These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24602376)

  • 41. Chromatographic and electrophoretic assessment of Filgrastim biosimilars in pharmaceutical formulations.
    Shaltout EL; Al-Ghobashy MA; Fathalla FA; Salem MY
    J Pharm Biomed Anal; 2014 Aug; 97():72-80. PubMed ID: 24816160
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The constitutional protection of trade secrets and patents under the Biologics Price Competition and Innovation Act of 2009.
    Epstein RA
    Food Drug Law J; 2011; 66(3):285-328. PubMed ID: 24505851
    [TBL] [Abstract][Full Text] [Related]  

  • 43. One-year assessment of joint procurement of pharmaceuticals in the public health sector in Jordan.
    Al-Abbadi I; Qawwas A; Jaafreh M; Abosamen T; Saket M
    Clin Ther; 2009 Jun; 31(6):1335-44. PubMed ID: 19695398
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Biosimilars: assessment of efficacy, safety and cost].
    Domínguez-Gil Hurlé A
    Farm Hosp; 2010 Mar; 34 Suppl 1():25-8. PubMed ID: 20920855
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Launch prices for new pharmaceuticals in the heavily regulated and subsidized Spanish market, 1995-2007.
    Puig-Junoy J; López-Valcárcel BG
    Health Policy; 2014 Jun; 116(2-3):170-81. PubMed ID: 24641938
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Feds Act to Boost Competition in the Biosimilars Market.
    Miller HI
    Mo Med; 2020; 117(3):196-198. PubMed ID: 32636543
    [No Abstract]   [Full Text] [Related]  

  • 47. A long war begins: biosimilars versus patented biologics.
    Bocquet F; Paubel P
    J Med Econ; 2015; 18(12):1071-3. PubMed ID: 26212478
    [No Abstract]   [Full Text] [Related]  

  • 48. Analysis of the Italian generic medicines retail market: recommendations to enhance long-term sustainability.
    Dylst P; Vulto A; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):33-42. PubMed ID: 25138241
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Why drug prices will go lower.
    Tully S
    Fortune; 1993 May; 127(9):56-8, 60, 62 passim. PubMed ID: 10125261
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An empirical analysis of the multimarket contact theory in pharmaceutical markets.
    Coronado J; Jiménez-Martín S; Marín PL
    Eur J Health Econ; 2014 Jul; 15(6):623-43. PubMed ID: 23818281
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
    Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
    Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epoetin biosimilars in Europe: five years on.
    Mikhail A; Farouk M
    Adv Ther; 2013 Jan; 30(1):28-40. PubMed ID: 23242745
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The comparability conundrum: biosimilars in the United States, Europe and Canada.
    Courage N; Parsons A
    Food Drug Law J; 2011; 66(2):203-24, i-ii. PubMed ID: 24505840
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biosimilars: impact of differences with Hatch-Waxman.
    Kowalchyk K; Crowley-Weber C
    Pharm Pat Anal; 2013 Jan; 2(1):29-37. PubMed ID: 24236968
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Competition and the Reference Pricing Scheme for pharmaceuticals.
    Ghislandi S
    J Health Econ; 2011 Dec; 30(6):1137-49. PubMed ID: 21937137
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Biosimilar filgrastim: from development to record].
    García Alfonso P
    Farm Hosp; 2010 Mar; 34 Suppl 1():19-24. PubMed ID: 20920854
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biotech innovators jump on biosimilars bandwagon.
    Moran N
    Nat Biotechnol; 2012 Apr; 30(4):297-9. PubMed ID: 22491261
    [No Abstract]   [Full Text] [Related]  

  • 58. Clinical development of biosimilars: an evolving landscape.
    Subramanyam M
    Bioanalysis; 2013 Mar; 5(5):575-86. PubMed ID: 23425273
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Public drug procurement: the lessons from a drug tender in a teaching hospital of a transition country.
    Milovanovic DR; Pavlovic R; Folic M; Jankovic SM
    Eur J Clin Pharmacol; 2004 May; 60(3):149-53. PubMed ID: 15057496
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biosimilar G-CSF (filgrastim) is effective for peripheral blood stem cell mobilization and non-cryopreserved autologous transplantation.
    Yafour N; Brahimi M; Osmani S; Arabi A; Bouhass R; Bekadja MA
    Transfus Clin Biol; 2013 Dec; 20(5-6):502-4. PubMed ID: 23916573
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.